In a year-long phase II trial, Ambroxol, a widely used cough medicine in Europe, showed target engagement in patients with ...

Treatment with ambroxol for symptoms of Parkinson’s disease dementia was safe, but its efficacy was undetermined in a small ...

Looking a treatment for symptoms of decline in thinking and reasoning skills? Recent study approves common cough syrup to ...

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

Ambroxol is commonly used as an expectorant in cough syrup, helping thin out mucus so people with respiratory illnesses can ...

A safe and affordable treatment to slow the advancement of Parkinson's dementia has emerged – in the form of a commonly ...

In a small clinical trial in Canada, a medicine commonly found in European cough syrups has shown early signs it might do ...

A recent phase 2 clinical trial reveals that Ambroxol, a common cough medicine, shows promise in stabilizing psychiatric symptoms and potentially slowing cognitive decline in Parkinson's disease ...

Ambroxol, a cough medication, may help stabilize the neuropsychiatric symptoms of Parkinson's disease dementia, a new study ...

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people ...

Ambroxol increased enzyme levels in Parkinson’s dementia patients, but showed no cognitive benefit in a year-long trial.

“Ambroxol was safe, well-tolerated, and demonstrated target engagement,” scientists wrote, however adding that the drug’s clinical effect on cognition was “not confirmed” in the study.